Background: Inflammatory bowel diseases patients eligible for biological therapy represent
a group with considerable disease burden and biologics only achieve 40% clinical …

Background and aims Therapy with two concomitant biologicals targeting different
inflammatory pathways has emerged as a new therapy option for treatment refractory …

Using 2 or more treatment modalities to achieve a synergistic effect in patients with refractory
inflammatory bowel disease (IBD) has been an area of focus for many years. This …

Background & Aims There is debate over whether patients with inflammatory bowel
diseases (IBD) treated with biologics that are not tumor necrosis factor antagonists (such as …

Background Comparisons of second‐line anti‐tumour necrosis factor (TNF) agents and
vedolizumab are sparse. Aim To evaluate the effectiveness of anti‐TNF agents compared to …

Uncertainty exists regarding safety and efficacy of dual biological therapy (DBT) in
inflammatory bowel disease. We present four cases of DBT in Crohn's disease. Three …

Current medical treatment for inflammatory bowel disease (IBD) does not achieve 100%
response rates, and a subset of refractory and severely ill patients have persistent active …

Current therapies used in the treatment of inflammatory bowel disease (IBD) are not effective
in all patients. Biologic agents result in approximately 40% remission rates at 1 year in …

Background and Aims We conducted a systematic review and meta-analysis to summarize
emerging data on the safety and effectiveness of dual biologic therapy in combination or …

Inflammatory bowel disease (IBD) is a chronic and disabling disorder. Severity of IBD is
prominent among refractory with patients with concomitant immune-mediated disorders …